WARNING ! This page is no longer updated !
We report below the forest plots for the main treatment comparisons.
Please choose a Treatment Comparison:
In this table, we report the main characteristics of the NRS identified.
The link in the column Overall risk of bias will give you access to a complete description of the assessment of each risk of bias domain with supports for judgement. The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column Full description will give you access to the general characteristics of the study.
The components included in the standard of care vary among the included studies. For example, the standard of care may include antiviral treatments in some studies, but not in others. We are in the process of contacting the study authors to obtain more information.
We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication. We perform daily database searches to identify if an included pre-print has been published in a scientific journal, and we will use the published paper to update our extraction.
Following the publication of an expression of concern by the Lancet (June 3, 2020) regarding the paper by Mandeep Mehra et al—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, and the retraction by 3 of the authors (June 4, 2020), we decided to delete data related to this study from our website
Trial | Comparisons | Design | Participants | Sample size | Overall risk of bias | Full description | |
---|---|---|---|---|---|---|---|
Treatment 1 | Treatment 2 | ||||||
ChiCTR2000029542 Huang M, J Mol Cell Biol, 2020 Full text Commentary |
Chloroquine | Lopinavir-Ritonavir | Non-randomized study | Patients with COVID-19 (moderate-severe) admitted to a single center China | N=22 | N/A | Full description |
N/A Shao Z, medRxiv, 2020 Full text Commentary |
Intravenous immunoglobulin | Standard care | Non-randomized study | Patients with confirmed COVID-19 (critical) admitted to 8 centers in China. | N=325 |
Serious Details |
Full description |
N/A Rajter J, medRxiv, 2020 Full text Commentary |
Ivermectin | Standard care | Non-randomized study | Patients with moderate, severe and critical confirmed COVID 19 hospitalized to four hospitals in USA | N=280 |
Serious Details |
Full description |
N/A Guaraldi G, Lancet Rheumatol, 2020 Full text Commentary |
Tocilizumab | Standard care | Non-randomized study | Patients with COVID-19 (severe) admitted to three centers in Italy | N=* | N/A | Full description |
* Giacomelli A, J Med Virol , 2020 Full text Pubpeer |
LPV/r+HCQ early | LPV/r+HCQ delayed | Non-randomized study | Patients with COVID-19 (mild-critical) admitted to a single center in Italy | N=* |
* Details |
Full description |
LPV/r+HCQ early | LPV/r+HCQ delayed |
* Details |
|||||
N/A Mikulska, M, medRxiv, 2020 Full text Commentary and Commentary |
Tocilizumab and/or Methylprednisolone | Standard care | Non-randomized study | Patients with COVID-19 pneumonia (severe) admitted to a single centre Italy | N=* |
Serious Details |
Full description |
N/A Albani F, medRxiv, 2020 Full text Commentary |
Corticosteroid | Standard care | Non-randomized study | Patients with COVID-19 severe admitted to a single center in Italy | N=1403 |
Serious Details |
Full description |
N/A Motta J, medRxiv, 2020, , Full text Commentary |
therapeutic enoxaparin or heparin | prophylactic enoxaparin or heparin | Non-randomized study | Patients with COVID-19 (moderate-severe) admitted to two centers in USA | N=* |
Serious Details |
Full description |
N/A Yu B, Sci China Life Sci, 2020 Full text Commentary |
Hydroxychloroquine | Standard care | Non-randomized study | Patients with confirmed COVID-19 (critical) admitted to a single center in the China. | N=550 |
Serious Details |
Full description |
N/A Mahevas M, BMJ, 2020 Full text Commentary Commentary |
Hydroxychloroquine | Standard care | Non-randomized study | Patients with COVID-19 (moderate), hospitalized and requiring oxygen, admitted to four centers in France | N=181 |
Moderate Details |
Full description |
N/A Geleris J, N Engl J Med, 2020 Full text Commentary |
Hydroxychloroquine | Standard care | Non-randomized study | Patients with confirmed COVID-19 (unclear severity) admitted to one center in the USA. | N=1085 |
Serious Details |
Full description |
N/A Liu, STH, medRxiv, 2020 Full text Commentary |
Convalescent plasma | Standard care | Non-randomized study | Patients with COVID-19 (moderate/Severe/Critical) admitted to a single centre in | N=* |
Moderate Details |
Full description |
N/A Somers EC, Clin Infect Dis, 2020 Full text Commentary |
Tocilizumab | Standard care | Non-randomized study | Patients with confirmed COVID-19 (critical) admitted to a single center in USA. | N=154 |
Serious Details |
Full description |
N/A Ip A, medRxiv, 2020 Full text Pubpeer |
Azithromycin | Standard care | Non-randomized study | Patients with confirmed COVID-19 hospitalized within a 13- hospital network | N=2512 |
Serious Details |
Full description |
Hydroxychloroquine + Azithromycin | Standard care |
Serious Details |
|||||
Hydroxychloroquine | Standard care |
Serious Details |
|||||
Tocilizumab | Standard care |
Serious Details |
|||||
NCT04366206 Rossi B, medRxiv, 2020 Full text Commentary |
Tocilizumab | Standard care | Non-randomized study | Patients with COVID-19 (severe) admitted to a single center in France. | N=168 |
Moderate Details |
Full description |
N/A Magagnoli J, Med, 2020 Full text Pubpeer |
Hydroxychloroquine + Azithromycin | Standard care | Non-randomized study | Patients with confirmed COVID-19 (moderate-severe) admitted to a multiple centers in USA. | N=368 |
Serious Details |
Full description |
Hydroxychloroquine | Standard care | ||||||
N/A Martínez-Sans J, medRxiv, 2020 Full text Commentary |
Tocilizumab | Standard care | Non-randomized study | Patients with confirmed COVID-19 admitted to 17 centers in Spain. | N=1229 |
Serious Details |
Full description |
* Sbidian E, medRxiv, 2020 Full text Pubpeer |
Hydroxychloroquine + Azithromycin | Standard care | Non-randomized study | Patients with COVID-19 admitted to 39 centers in France. | N=4642 |
Moderate Details |
Full description |
Hydroxychloroquine | Standard care | ||||||
EUPAS34753 Fernández Cruz A, AAC ASM, 2020 Full text Commentary |
Methylprednisolone | Standard care | Non-randomized study | Patients with COVID-19 pneumonia (moderate, severe, critical) and complicated with ARDS and/or an hyperinflammatory syndrome admitted to a single center in Spain | N=463 |
Serious Details |
Full description |
NCT04323592 Salton F, medRxiv, 2020 Full text |
Methylprednisolone | Standard care | Non-randomized study | Patients with confimed COVID-19 pneumonia(severe) admitted to fourteen centers in Italy | N=173 |
Serious Details |
Full description |
* Wu J, medRxiv, 2020 Full text Pubpeer |
Corticosteroids (HC, MPS, DM) 6 days | Standard care | Non-randomized study | Patients with COVID-19 (severe-critical) admitted to two centers China | N=720 |
Serious Details |
Full description |
Corticosteroids (HC, MPS, DM) 5 days | Standard care | ||||||
N/A Majmundar M, medRxiv, 2020 Full text Commentary |
Corticosteroids (MPS/Pred/HC/D) | Standard care | Non-randomized study | Patients with COVID-19 (moderate-severe) admitted to a single center USA | N=205 |
Serious Details |
Full description |
N/A Arshad S, Int J Infect Dis, 2020 Full text Commentary |
Hydroxychloroquine | Standard Care | Non-randomized study | Patients with COVID-19 (moderate-critical) admitted to 6 centers in USA | N=2541 |
Serious Details |
Full description |
Freedberg, DE, medRxiv, 2020 study assessing Famotidine vs Standard of Care was excluded from the systematic review due to prevalent user bias